Breast Cancer Treatment Based on Organ-like Culture

Air Force Military Medical University of People's Liberation Army

Status: Unknown

Conditions: Breast Cancer Organoids

Treatments: Drug: Eribulin mesylate; Drug: Fulvestrant; Drug: Fluorouracil; Drug: Trastuzumab; Drug: Pirarubicin hydrochloride; Drug: Pattozumab; Drug: Aidi Injection; Drug: Capecitabine; Drug: Recombinant Human Endostatin; Drug: Cyclophosphamide; Drug: Toremifene citrate; Drug: Ear particles; Drug: Anastrozole; Drug: Olaparib; Drug: Methotrexate; Drug: Tamoxifen citrate; Drug: Doxorubicin Hydrochloride; Drug: Letrozole; Drug: Cisplatin; Drug: Pyrrolidine; Drug: Epirubicin hydrochloride; Drug: Exemestane; Drug: Gemcitabine; Drug: Apatinib mesylate; Drug: Vinorelbine tartrate; Drug: Ixabepilone; Drug: Bevacizumab; Drug: Carboplatin; Drug: Paclitaxel

Study type: Observational

Funder types: Other

Identifiers

NCT03925233

KY20182079-F-1

Details and patient eligibility

About

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Enrollment: 300 estimated patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form

Exclusion criteria

Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study.

Other investigators believe that patients who are not suitable for this study group

Trial design

300 participants in 3 patient groups

HER2+ Breast Cancer

Treatment:

Drug: Anastrozole

Drug: Eribulin mesylate

Drug: Cyclophosphamide

Drug: Olaparib

Drug: Methotrexate

Drug: Pyrrolidine

Drug: Tamoxifen citrate

Drug: Pattozumab

Drug: Fulvestrant

Drug: Gemcitabine

Drug: Toremifene citrate

Drug: Trastuzumab

Drug: Bevacizumab

Drug: Ear particles

Drug: Capecitabine

Drug: Ixabepilone

Drug: Pirarubicin hydrochloride

Drug: Aidi Injection

Drug: Doxorubicin Hydrochloride

Drug: Fluorouracil

Drug: Carboplatin

Drug: Apatinib mesylate

Drug: Paclitaxel

Drug: Letrozole

Drug: Cisplatin

Drug: Epirubicin hydrochloride

Drug: Exemestane

Drug: Vinorelbine tartrate

Drug: Recombinant Human Endostatin

ER+ Breast Cancer

Treatment:

Drug: Anastrozole

Drug: Eribulin mesylate

Drug: Cyclophosphamide

Drug: Olaparib

Drug: Methotrexate

Drug: Pyrrolidine

Drug: Tamoxifen citrate

Drug: Pattozumab

Drug: Fulvestrant

Drug: Gemcitabine

Drug: Toremifene citrate

Drug: Trastuzumab

Drug: Bevacizumab

Drug: Ear particles

Drug: Capecitabine

Drug: Ixabepilone

Drug: Pirarubicin hydrochloride

Drug: Aidi Injection

Drug: Doxorubicin Hydrochloride

Drug: Fluorouracil

Drug: Carboplatin

Drug: Apatinib mesylate

Drug: Paclitaxel

Drug: Letrozole

Drug: Cisplatin

Drug: Epirubicin hydrochloride

Drug: Exemestane

Drug: Vinorelbine tartrate

Drug: Recombinant Human Endostatin

Triple Negative Breast Cancer

Treatment:

Drug: Anastrozole

Drug: Eribulin mesylate

Drug: Cyclophosphamide

Drug: Olaparib

Drug: Methotrexate

Drug: Pyrrolidine

Drug: Tamoxifen citrate

Drug: Pattozumab

Drug: Fulvestrant

Drug: Gemcitabine

Drug: Toremifene citrate

Drug: Trastuzumab

Drug: Bevacizumab

Drug: Ear particles

Drug: Capecitabine

Drug: Ixabepilone

Drug: Pirarubicin hydrochloride

Drug: Aidi Injection

Drug: Doxorubicin Hydrochloride

Drug: Fluorouracil

Drug: Carboplatin

Drug: Apatinib mesylate

Drug: Paclitaxel

Drug: Letrozole

Drug: Cisplatin

Drug: Epirubicin hydrochloride

Drug: Exemestane

Drug: Vinorelbine tartrate

Drug: Recombinant Human Endostatin